Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies.
Featured
Latest Company Reports
- BBIOBridgeBio Pharma Inc
Positive Outlook for BridgeBio Pharma's Rare-Disease Pipeline As Attruby Is Poised To Support Growth
- Rating
- Price
- $66.90
- Fair Value
- Kg
- Uncertainty
- LOCK|mW <v?Yk
- Economic Moat
- LOCK|xZw
- Capital Allocation
- LOCK|!?YqVG
- CIThe Cigna Group
After Investment Year in 2026, Cigna Aims to Reaccelerate Profit Growth
- Rating
- Price
- $267.96
- Fair Value
- NX^
- Uncertainty
- LOCK|$R
- Economic Moat
- LOCK|gy#J
- Capital Allocation
- LOCK|?<td$>G
- 01833Ping An Healthcare And Technology Co Ltd Ordinary Shares
Ping An Health Sees Long-Term Execution Risks as Outlook Muted
- Rating
- Price
- HK$6.16
- Fair Value
- LOCK|Xx
- Uncertainty
- LOCK|mZB
- Economic Moat
- LOCK|JS
- Capital Allocation
- LOCK|$$$r^^
- NTLAIntellia Therapeutics Inc
No-Moat Intellia Therapeutics Provides Pure-Play, Long-Term Exposure to Gene Editing Therapies
- Rating
- Price
- $12.12
- Fair Value
- $J
- Uncertainty
- LOCK|@j >!?YK
- Economic Moat
- LOCK|&nv
- Capital Allocation
- LOCK|#PZdjX
- 00241Alibaba Health Information Technology Ltd
Alibaba Health Expected To See Medium-Term Growth Slowing Due to Weakness in Health Product Sales
- Rating
- Price
- HK$2.82
- Fair Value
- Y#
- Uncertainty
- LOCK|sf rXCy#
- Economic Moat
- LOCK|?@#P#
- Capital Allocation
- LOCK|W<lN%B
- 06618JD Health International Inc
JD Health Ramping Up Sales as Consumers Get More Comfortable With Healthcare E-Commerce
- Rating
- Price
- HK$34.64
- Fair Value
- tR
- Uncertainty
- LOCK|T! ?^s!<
- Economic Moat
- LOCK|S#^G
- Capital Allocation
- LOCK|Rbv#d%
- 01801Innovent Biologics Inc
Innovent Sets 2030 Revenue Forecast as GLP-1 and Oncology Treatments Are Main Drivers
- Rating
- Price
- HK$96.25
- Fair Value
- LOCK|?j
- Uncertainty
- LOCK|$c &p>#
- Economic Moat
- LOCK|?%#q
- Capital Allocation
- LOCK|^HYYWv%L
- TLXTelix Pharmaceuticals Ltd Ordinary Shares
Telix Pharmaceuticals Has a Positive Outlook Despite High Uncertainty
- Rating
- Price
- A$15.16
- Fair Value
- R>
- Uncertainty
- LOCK|Lh &T$z
- Economic Moat
- LOCK|yc?
- Capital Allocation
- LOCK|ScRG!&?
- ARGXargenx SE
No-Moat Argenx's Growth Led by Vyvgart; Pipeline Brings Long-Term Diversification
- Rating
- Price
- €841.60
- Fair Value
- LOCK|r!
- Uncertainty
- LOCK|$Z$
- Economic Moat
- LOCK|!^Z
- Capital Allocation
- LOCK|<#ztKT
- CTECConvatec Group PLC
Convatec: Well Postioned for Acceleration Beyond 2026
- Rating
- Price
- GBX216.80
- Fair Value
- Kmw
- Uncertainty
- LOCK|$GLf<
- Economic Moat
- LOCK|>r##l
- Capital Allocation
- LOCK|yb^YXnx
- YPSNYpsomed Holding AG
Ypsomed: Platform-Based Device Model Positions It to Capture Biologics Growth Tailwind
- Rating
- Price
- CHF 357.80
- Fair Value
- wpv
- Uncertainty
- LOCK|V$
- Economic Moat
- LOCK|G@!&n
- Capital Allocation
- LOCK|?s!mJY
- VRTXVertex Pharmaceuticals Inc
Narrow-Moat Vertex's Strong CF Cash Flows Support Portfolio Diversification and Long-Term Growth
- Rating
- Price
- $506.74
- Fair Value
- LOCK|ff
- Uncertainty
- LOCK|WX
- Economic Moat
- LOCK|?K<kx
- Capital Allocation
- LOCK|M<?y?>!
- ERFEurofins Scientific SE
Eurofins: Hub-and-Spoke Network Expected To Drive Long-Term Efficiency Gains
- Rating
- Price
- €74.54
- Fair Value
- zTb
- Uncertainty
- LOCK|bY@?^
- Economic Moat
- LOCK|!c@L
- Capital Allocation
- LOCK|h>Pz@Y#
- GETI BGetinge AB Class B
Getinge's Fundamentals Intact as Demand for High-Margin Products Remains Strong
- Rating
- Price
- SEK 247.20
- Fair Value
- gbl
- Uncertainty
- LOCK|!Rv
- Economic Moat
- LOCK|<YS
- Capital Allocation
- LOCK|XK^gFJl
- TEVATeva Pharmaceutical Industries Ltd
Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margin
- Rating
- Price
- $39.31
- Fair Value
- !?f
- Uncertainty
- LOCK|%v
- Economic Moat
- LOCK|@ByW%
- Capital Allocation
- LOCK|@!&<!^?V
Largest Stocks in the Healthcare Sector
|
1-Day Chart
|
Name
|
Industry
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Drug Manufacturers - General | LOCK|j^$@!xH | LOCK|M< | $1T | |||
| Johnson & Johnson
JNJ
| Drug Manufacturers - General | LOCK|Ml%tLWL | LOCK|^z | $623B | |||
| AbbVie Inc
ABBV
| Drug Manufacturers - General | LOCK|@?>WyF | LOCK|lfV | $459B | |||
| Merck & Co Inc
MRK
| Drug Manufacturers - General | LOCK|?>&@ZNr | LOCK|#! | $355B | |||
| UnitedHealth Group Inc
UNH
| Healthcare Plans | LOCK|k%V$?y | LOCK|#B<sg | $328B | |||
| Novartis AG ADR
NVS
| Drug Manufacturers - General | LOCK|m@hVh?# | LOCK|nh | $268B | |||
| AstraZeneca PLC
AZN
| Drug Manufacturers - General | LOCK|m%!^&^vX | LOCK|B& | $248B | |||
| Thermo Fisher Scientific Inc
TMO
| Diagnostics & Research | LOCK|F?>tTm!g | LOCK|!<! | $241B | |||
| Amgen Inc
AMGN
| Drug Manufacturers - General | LOCK|GYP&mT@! | LOCK|$L | $220B | |||
| Gilead Sciences Inc
GILD
| Drug Manufacturers - General | LOCK|x!xMt%S | LOCK|TC | $183B |
More in Healthcare
This Turnaround Stock Is Up and Still 38% Undervalued
This company and its stock are making a comeback.
3 Stocks to Sell and 3 Stocks to Buy for September
Plus, whether Nvidia, Marvell Technology, or Salesforce looks attractive after earnings.
Veeva Earnings: Customer Wins and AI Progress Fuel Momentum
Veeva puts aside the artificial intelligence-concerned naysayers and touts continued business strength.
Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology
We’ve raised our fair value estimates of Moderna and Merck stock.
Why This Growth Stock Manager Likes Both the AI Trade and Eli Lilly
Despite the cash burn at hyperscalers, the AI boom is only in its early stages, and the benefits are spreading, says Jennison’s Boyer.
Eli Lilly Earnings: Strong Q2 and Higher Margin Expectations
We’ve raised our fair value estimate of Lilly stock.
Novo Nordisk Earnings: Price Pressure Growing with Oral Cash Pay Success and Another Cagrisema Miss
We are lowering our fair value estimate after reducing our long-term gross margin forecast, cagrisema expectations, and stage 2 growth assumptions.
CVS Health Earnings: Aetna Margin Improvement Boosts 2026 Outlook
We’ve raised our fair value estimate of CVS stock.
Pfizer Earnings: Strong Growth for Newer Drugs Counters Covid Declines
We still need to see significant pipeline progress to gain confidence in Pfizer’s goal of high-single-digit top-line growth in 2028-33.
AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads
Bristol’s massive 2028 patent cliff could fit well with Astra’s more limited patent exposure.
United States